Revenue, 2025

USD 6.52 Billion

Forecast, 2035

USD 13.82 Billion

CAGR, 2026-2035

7.8%

Report Coverage

Global

Breast Biopsy Devices Market Trends for 2026

The global breast biopsy devices market size was estimated at USD 6.52 billion in 2025 and is predicted to increase from USD 7.03 billion in 2026 to approximately USD 13.82 billion by 2035, expanding at a CAGR of 7.8% from 2026 to 2035. The overall market progression is propelled by the massive burden of breast cancer cases, widespread demand for minimally invasive procedures, & continuous breakthroughs in AI-powered solutions. Additionally, giant firms are developing portable, wireless localization & robot-assisted systems.

Key Takeaways

• Breast biopsy devices sector pushed the market to USD 7.03 billion by 2026.
• Long-term projections show USD 13.82 billion valuation by 2035.
• Growth is expected at a steady CAGR of 7.8% in between 2026 to 2035.
• North America accounted for the largest share of 38% of the market in 2025.
• Asia Pacific held 22% revenue share of the market in 2025 & is expected to be the fastest-growing region at 9.20% CAGR in the studied years.
• By product type, the needle-based biopsy instruments segment led with 58% share of the breast biopsy devices market in 2025.
• By product type, the guidance systems segment captured 20% share in 2025 & is expected to grow at 9.50% CAGR during the forecast period.
• By technique, the minimally invasive biopsy segment held a major share of 72% of the market in 2025 & is expected to witness rapid growth at 8.6% CAGR in the coming years.
• By imaging modality, the stereotactic X-ray segment dominated with 40% share of the market in 2025.
• By imaging modality, the ultrasound segment held 35% share in 2025 & is expected to grow at a rapid CAGR of 8.4% during 2026-2035.
• By end user, the hospitals segment captured the largest share of 55% of the market in 2025.
• By end user, the diagnostic imaging centers segment held 30% share of the breast biopsy devices market in 2025 & is expected to grow fastest at 8.5% CAGR in the studied years.
• By application, the breast cancer diagnosis segment led with 88% revenue share of the market in 2025.
• By application, the research & clinical trials segment captured 12% share in 2025 & is expected to grow at 8.80% CAGR during the forecast period.

What are the Breast Biopsy Devices & Their Major Catalysts?

The use of specialized, minimally invasive medical instruments, i.e. breast biopsy devices, is widely leveraged in the removal of small samples of breast tissue for cancer analysis. Whereas, the breast biopsy devices market growth is driven by the notable rise in cases of breast cancer, a substantial shift towards vacuum-assisted biopsy (VAB) & core needle biopsy (CAB) to foster less invasions & rapid recovery.

How is AI Governing the Breast Biopsy Devices Market?

Specifically, the adoption of AI-CAD tools shows efficient spotting of clear signs of cancer in dense breast tissue. Besides this, AI has broader applications when combined with ultrasound devices, which offer real-time, automated analysis of breast lesions & further increase the operator’s efficiency by targeting the proper site at the time of biopsy. In addition, AI tools assist with the segmentation & categorization of lesions based on BI-RADS criteria during ultrasound.

Trends & Future Outlook of the Breast Biopsy Devices Market

Stepping Towards Wireless Localization

The market firms are actively using magnetic & RFID-based localization tags to replace traditional wire localization to bolster patient comfort & scheduling flexibility.

Promoting Disposable & Portable Devices

The globe is surging demand for single-use, disposable needles & portable, user-friendly ultrasound biopsy systems to decline cross-contamination challenge.

Emerging Robot-Assisted Biopsy Systems

Pivotal research studies are implementing robot-assisted ultrasound-guided biopsy systems to push automation, optimize maneuvering, & lower manual error.

Quick Facts Table

Segmental Analysis

Product Type Insights

The Needle-Based Biopsy Instruments Segment Led the Market in 2025

In 2025, the needle-based biopsy instruments segment captured 58% share of the breast biopsy devices market. Drivers include the increase in breast cancer incidence, broader preference for outpatient procedures, & the emergence of specialized needles for higher-quality tissue samples. Ongoing developments cover the use of novel 8-gauge (8G) & 7-gauge (7G) needles for robust tissue yield, specifically for non-palpable lesions.

Although the guidance systems segment held the second-largest share of 20% in 2025, it is predicted to expand at 9.50% CAGR. Patients are seeking systems with minimal anxiety, pain, & recovery period over surgical biopsies, while advanced guidance is supporting the reduction of false negatives & ensures precise sampling of non-palpable, BIRADS 4-5 lesions.

The localization wires segment captured 12% share in 2025, due to the higher cost-effectiveness and increased compatibility with diverse imaging techniques, like stereotactic mammography, ultrasound, & MRI.

The biopsy tables segment accounted for 10% share of the market. They are a common part of Stereotactic Guided Systems, which enable radiologists to accurately position patients for breast imaging & tissue sampling.

Technique Insights

The Minimally Invasive Biopsy Segment Dominated the Market in 2025

The minimally invasive biopsy segment captured 72% share in 2025 & is estimated to grow at 8.6% CAGR in the breast biopsy devices market. Apart from the global preference, the surging breast cancer cases require integration of this technique with expanded mammography & ultrasound screening programs. Also, the latest trend includes 3D tomosynthesis, MRI, & AI-enabled targeting, to enhance accuracy in targeting non-palpable lesions & microcalcifications.

The surgical biopsy segment held 28% share in 2025, due to the escalating need for the absolute diagnosis when less invasive methods, like core needle biopsy (CNB), are insufficient, indefinite, or indicate high-risk lesions. Several times, a surgeon uses radar technology to locate the lesion, to facilitate greater precision & flexibility in surgical timing.

Imaging Modality Insights

The Stereotactic X-ray Segment Was Dominant in the Market in 2025

In 2025, the stereotactic X-ray segment led with 40% share of the breast biopsy devices market. Particular adoption of stereotactic biopsy is significant in the detection of microcalcifications & non-palpable lesions, which elevates early diagnosis. Whereas, Contrast-Enhanced Stereotactic Biopsy (CRSB) executes as an inexpensive, more accessible option to MRI-guided biopsy for finding areas of neoangiogenesis.

Moreover, the ultrasound segment accounted for 35% share in 2025 & is anticipated to register rapid growth at 8.4% CAGR. The worldwide accelerating preference for ultrasound-guided techniques by patients & clinicians offers wider affordability & precise results with reduced discomfort. Gradual breakthroughs encourage 3D ultrasound, which facilitates reconstructed images in coronal, sagittal, & transverse planes, with extensive evaluation of tumor margins.

The MRI segment captured 25% share of the market, due to its higher sensitivity for the detection of earlier cancer, the development of high-risk patients, & the rising need for the determination of the full extent of cancer. Immersive trends are following Abbreviated MRI protocols to lower scan times, which leads to affordable screening & biopsy planning.

End User Insights

The Hospitals Segment Led the Market in 2025

The hospitals segment dominated with 55% share of the breast biopsy devices market in 2025. Dominance is fueled by the strong access to specialized radiologists & pathologists, instant on-site care, & the ability to conduct minimally invasive procedures as outpatients. With a perfect treatment strategy, hospitals leverage advanced imaging to guide needles accurately to the suspicious area.

Whereas the diagnostic imaging centers segment captured 30% share in 2025 & is estimated to expand at 8.5% CAGR. They mainly provide specialized radiologists, who read the scans & operate the biopsies, work with pathologists to find if abnormalities are benign, suspicious, or malignant. Also, explore period diagnostics with biopsies that are conducted within a week of starting abnormal screening.

The ambulatory surgical centers segment held 15% share, due to their safe, robust, and inexpensive option to conventional hospital inpatient environments. They usually specializes in same-day procedures, enabling patients to return home shortly after their biopsy.

Application Insights

The Breast Cancer Diagnosis Segment Dominated the Market in 2025

In 2025, the breast cancer diagnosis segment held a major share of 88% of the breast biopsy devices market. According to a study, there were nearly 2.3 million breast cancer cases around the globe, with rising demand for early diagnosis & the use of the latest MIS, driving the segmental dominance. Key efforts are emphasising improvements in diagnostic accuracy using AI & liquid biopsies for real-time monitoring.

However, the research & clinical trials segment held 12% share & is predicted to expand rapidly at 8.80% CAGR. This is widely driven by the notable need to recognize tumor biology at a molecular level, recruit patients for targeted therapies, & evaluate drug efficacy in real-time. Trend has been using serial biopsies to investigate why treatments cease working, & assists researchers in identifying novel mechanisms of drug resistance.

Regional Insights

What Made North America Dominant in the Market in 2025?

North America registered dominance with 38% share of the breast biopsy devices market, due to the well-established healthcare infrastructure & massive demand for minimally invasive procedures in the growing breast cancer cases. Alongside, the region is fostering rigorous reimbursement policies & empowering breast cancer awareness programs to promote advanced biopsy approaches.

For instance,

• In October 2025, BD announced an immersive effort for the In Celebration of Her program, to broaden breast cancer awareness, early detection & patient support.

U.S. Market Trends

The U.S. market was the largest contributor to the market, as it is reinforcing consumables to meet the requirement for sterile, single-use components in biopsy procedures. Also, the U.S. is focusing on AI-driven imaging software to boost lesion detection accuracy & further combine real-time feedback loops with imaging platforms & biopsy devices.

Expansion of Programs & Lucrative Cancer Instances are Driving the Asia Pacific

Asia Pacific is anticipated to expand at the fastest CAGR of 9.20% in the breast biopsy devices market. Many APAC governments & private organizations have widened their breast cancer screening programs, especially in India & China, which has spurred the adoption of biopsy devices for prior diagnosis. In South Korea, the market has recorded a major rise in breast cancer in women in their 20s and 30s.

India Market Trends

The Indian market is actively revolutionizing innovative techniques, like Vacuum-Assisted Breast Biopsy (VABB) & AI-assisted imaging.

For instance,

• In January 2026, Apollo Athenaa Women’s Cancer Centre unveiled MRI-Guided Vacuum-Assisted Breast Biopsy (MRI-Guided VABB) to foster early detection of breast cancer cases

Breast Biopsy Devices Market- Supply China Analysis

R&D

• Leaders are implementing identification of clinical needs, designing & engineering, then preclinical testing and validation solutions
• Key Players: Hologic, Inc., Devicor Medical Products, Inc., Becton, Dickinson and Company (BD), etc.

 Clinical Trials & Regulatory Approvals

• This majorly focuses on studying safety, efficacy, and ease of use as compared to existing gold standard techniques, with subsequent 510(k) clearance, coupled with a Premarket Approval (PMA). 
• Key Players: Mayo Clinic, University of California, San Diego, AURA Health Technologies, etc.

Patient Support & Services

• A key aim includes patient comfort, safety, & convenience, typically facilitating minimally invasive alternatives to surgical biopsies in outpatient settings.
• Key Players: GE HealthCare, Merit Medical Systems, Inc., Siemens Healthineers, etc.

Key Players' Offerings in the Breast Biopsy Devices Market

SWOT Analysis

Strengths

• Especially, Vacuum-assisted devices give very low false-negative rates as compared to traditional core needle biopsy.
• Under stereotactic guidance, these devices are highly efficient at recording microcalcifications, which are early signs of cancer.

Weaknesses

• Sometimes, any needle biopsy can provide indefinite results & false negatives.
• A huge use of ultrasound-guided biopsies shows a robust dependence on specialized operators to keep the needle and lesion in the imaging plane.

Opportunities

• Prominent use of AI will bolster image interpretation, enhance lesion targeting, & simplify workflow efficiency, with increased diagnostic accuracy by nearly 15%.
• Firms will promote MRI-safe robotic assistants to boost precision and lower surgical risks by up to 20%.

Threats

• Higher initial investment raises barriers to adopting these devices.
• Strict, time-consuming, and expensive regulatory approval processes can delay novel product rollouts.

What are the Latest Developments in the Breast Biopsy Devices Market?

• In February 2026, Mammotome launched the Mammotome Prima MR Dual Vacuum-Assisted Breast Biopsy System.
• In January 2026, iSono Health commercially launched ATUSA, an FDA-cleared, wearable & automated 3D quantitative breast ultrasound platform.
• In July 2025, SimonMed Imaging unveiled Mammogram+ and Mammogram+ Heart, two new AI-powered mammogram services focused on enhancing early detection & advancing preventative care in breast & heart issues.

Segments Covered in the Report

By Product Type

• Needle-Based Biopsy Instruments
  • Core Needle Biopsy (CNB) Devices
  • Fine Needle Aspiration (FNA) Devices
  • Vacuum-Assisted Biopsy (VAB) Devices
• Localization Wires
• Biopsy Tables
• Guidance Systems
  • Stereotactic Guidance Systems
  • Ultrasound-Guided Systems
  • MRI-Guided Systems

By Technique

• Minimally Invasive Biopsy
  • Core Needle Biopsy
  • Vacuum-Assisted Biopsy
  • Fine Needle Aspiration
• Surgical Biopsy
  • Incisional Biopsy
  • Excisional Biopsy

By Imaging Modality

• Stereotactic X-ray
• Ultrasound
• MRI

By End User

• Hospitals
• Diagnostic Imaging Centers
• Ambulatory Surgical Centers

By Application

• Breast Cancer Diagnosis
• Research & Clinical Trials

By Region

• North America
  • U.S.
  • Canada 
  • Mexico 
  • Rest of North America
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America
• Europe 
  • Western Europe 
    • Germany 
    • Italy
    • France
    • Netherlands
    • Spain
    • Portugal 
    • Belgium
    • Ireland
    • UK 
    • Iceland 
    • Switzerland
    • Poland
    • Rest of Western Europe
  • Eastern Europe 
    • Austria
    • Russia & Belarus 
    • Türkiye
    • Albania 
    • Rest of Eastern Europe 
• Asia Pacific
  • China 
  • Taiwan
  • India 
  • Japan 
  • Australia and New Zealand
  • ASEAN Countries (Singapore, Malaysia)
  • South Korea 
  • Rest of APAC 
• MEA 
  • GCC Countries
    • Saudi Arabia 
    • United Arab Emirates (UAE)
    • Qatar 
    • Kuwait 
    • Oman 
    • Bahrain 
  • South Africa
  • Egypt 
  • Rest of MEA